RANBP17

Summary

RANBP17 (RAN binding protein 17, HGNC:14428) is a protein-coding gene on chromosome 5q35.1, encoding Ran-binding protein 17 (Q9H2T7). May function as a nuclear transport receptor.

The transport of protein and large RNAs through the nuclear pore complexes (NPC) is an energy-dependent and regulated process. The import of proteins with a nuclear localization signal (NLS) is accomplished by recognition of one or more clusters of basic amino acids by the importin-alpha/beta complex; see MIM 600685 and MIM 602738. The small GTPase RAN (MIM 601179) plays a key role in NLS-dependent protein import. RAN-binding protein-17 is a member of the importin-beta superfamily of nuclear transport receptors.

Source: NCBI Gene 64901 — RefSeq curated summary.

At a glance

• GWAS associations: 9
• Clinical variants (ClinVar): 223 total
• MANE Select transcript: NM_022897

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14428
Approved symbol	RANBP17
Name	RAN binding protein 17
Location	5q35.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000204764
Ensembl biotype	protein_coding
OMIM	606141
Entrez	64901

Gene structure

Transcript identifiers

Ensembl transcripts: 24 — 8 protein_coding_CDS_not_defined, 7 nonsense_mediated_decay, 5 protein_coding, 4 retained_intron

ENST00000389118, ENST00000443155, ENST00000517629, ENST00000518492, ENST00000519130, ENST00000519256, ENST00000519944, ENST00000519949, ENST00000520586, ENST00000520864, ENST00000520879, ENST00000521165, ENST00000521759, ENST00000521834, ENST00000522066, ENST00000522380, ENST00000522533, ENST00000522734, ENST00000523189, ENST00000523665, ENST00000523727, ENST00000524364, ENST00000961945, ENST00000961946

RefSeq mRNA: 1 — MANE Select: NM_022897 NM_022897

CCDS: CCDS34287

Canonical transcript exons

ENST00000523189 — 28 exons

Exon	Start	End
ENSE00001473667	170953597	170953702
ENSE00001473671	170916465	170916584
ENSE00001473672	170914167	170914240
ENSE00001473674	170910969	170911134
ENSE00002690636	170862018	170862051
ENSE00003465000	171221758	171221840
ENSE00003515094	171183322	171183430
ENSE00003524506	170881806	170881896
ENSE00003537276	170918713	170918859
ENSE00003539375	171295887	171296014
ENSE00003555773	171293883	171293981
ENSE00003564267	170892387	170892553
ENSE00003584457	171298762	171300015
ENSE00003592947	170919441	170919613
ENSE00003601758	170968242	170968377
ENSE00003612618	171171206	171171286
ENSE00003630608	171205524	171205612
ENSE00003631913	170909661	170909765
ENSE00003637617	171170130	171170203
ENSE00003638179	171242682	171242820
ENSE00003641619	171183167	171183230
ENSE00003641733	171199670	171199773
ENSE00003646920	170878097	170878243
ENSE00003648152	171240928	171241142
ENSE00003659704	170924357	170924550
ENSE00003675311	170896050	170896115
ENSE00003679237	171213631	171213738
ENSE00003681284	171265681	171265847

Expression profiles

Bgee: expression breadth ubiquitous, 197 present calls, max score 94.97.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.2120 / max 104.1038, expressed in 1240 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
60166	3.1079	1016
60165	2.1041	949

Top tissues by expression

272 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	94.97	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	93.20	gold quality
adrenal tissue	UBERON:0018303	92.11	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	88.22	gold quality
right testis	UBERON:0004534	87.51	gold quality
left testis	UBERON:0004533	87.43	gold quality
testis	UBERON:0000473	86.16	gold quality
sperm	CL:0000019	83.69	gold quality
right uterine tube	UBERON:0001302	83.62	gold quality
ventricular zone	UBERON:0003053	83.10	gold quality
sural nerve	UBERON:0015488	81.84	gold quality
male germ cell	CL:0000015	81.37	gold quality
left lobe of thyroid gland	UBERON:0001120	81.25	gold quality
right adrenal gland cortex	UBERON:0035827	81.15	gold quality
minor salivary gland	UBERON:0001830	81.14	gold quality
right lobe of thyroid gland	UBERON:0001119	80.85	gold quality
right adrenal gland	UBERON:0001233	80.81	gold quality
thyroid gland	UBERON:0002046	80.61	gold quality
body of pancreas	UBERON:0001150	80.33	gold quality
cortical plate	UBERON:0005343	80.21	gold quality
left adrenal gland cortex	UBERON:0035825	80.19	gold quality
endometrium	UBERON:0001295	80.02	gold quality
left adrenal gland	UBERON:0001234	79.99	gold quality
adrenal gland	UBERON:0002369	79.81	gold quality
pancreatic ductal cell	CL:0002079	79.51	gold quality
stromal cell of endometrium	CL:0002255	79.49	gold quality
tendon	UBERON:0000043	79.23	gold quality
upper lobe of left lung	UBERON:0008952	79.09	gold quality
corpus callosum	UBERON:0002336	78.93	gold quality
adrenal cortex	UBERON:0001235	78.72	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.80
E-GEOD-124858	no	275.73

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): MYOD1

miRNA regulators (miRDB)

67 targeting RANBP17, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-4778-3P	99.93	70.40	1818
HSA-MIR-338-5P	99.92	72.34	2951
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-5682	99.89	72.56	1005
HSA-MIR-3140-3P	99.88	68.47	2069
HSA-MIR-3919	99.87	69.45	2489
HSA-MIR-659-3P	99.85	70.69	1620
HSA-MIR-576-5P	99.84	70.46	2582
HSA-MIR-6844	99.82	70.69	2423
HSA-MIR-2052	99.79	69.37	2031
HSA-MIR-6762-3P	99.66	66.94	1188
HSA-MIR-10394-5P	99.65	66.83	1852
HSA-MIR-1205	99.65	66.76	1826
HSA-MIR-6516-3P	99.65	68.57	1238
HSA-MIR-3158-5P	99.65	67.51	1763
HSA-MIR-567	99.63	68.57	1219
HSA-MIR-6757-3P	99.63	66.88	1089
HSA-MIR-4499	99.62	67.29	1470
HSA-MIR-3942-3P	99.57	69.03	2854
HSA-MIR-510-3P	99.54	70.06	2965
HSA-MIR-3612	99.45	66.02	1333
HSA-MIR-650	99.45	65.77	1309
HSA-MIR-372-5P	99.41	69.11	2299

Literature-anchored findings (GeneRIF, showing 3)

• These biochemical and functional data reveal RANBP16 and RANBP17 as novel regulators of E2A protein action, and demonstrate specific interaction of E12 with RANBP17. (PMID:20503194)
• The importin beta superfamily member RanBP17 exhibits a role in cell proliferation and is associated with improved survival of patients with HPV+ HNSCC. (PMID:35850701)
• RANBP17 Overexpression Restores Nucleocytoplasmic Transport and Ameliorates Neurodevelopment in Induced DYT1 Dystonia Motor Neurons. (PMID:38438257)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
mus_musculus	Ranbp17	ENSMUSG00000040594
rattus_norvegicus	Ranbp17	ENSRNOG00000005042
drosophila_melanogaster	Ranbp16	FBGN0053180
caenorhabditis_elegans		WBGENE00007952

Paralogs (2): XPO7 (ENSG00000130227), XPO4 (ENSG00000132953)

Protein

Protein identifiers

Ran-binding protein 17 — Q9H2T7 (reviewed: Q9H2T7)

All UniProt accessions (7): E5RHX1, Q9H2T7, H0YAS2, H0YBM6, H0YBY7, Q546R4, Q8IVM9

UniProt curated annotations — full annotation on UniProt →

Function. May function as a nuclear transport receptor.

Subunit / interactions. Binds to nucleoporins and the GTP-bound form of Ran.

Subcellular location. Cytoplasm. Nucleus. Nuclear pore complex.

Tissue specificity. Highly expressed in testis, moderately in pancreas and weakly in other tissues studied.

Similarity. Belongs to the exportin family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9H2T7-1	1	yes
Q9H2T7-2	2

RefSeq proteins (1): NP_075048* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001494	Importin-beta_N	Domain
IPR011989	ARM-like	Homologous_superfamily
IPR016024	ARM-type_fold	Homologous_superfamily
IPR044189	XPO4/7-like	Family
IPR057947	TPR_XPO7/RBP17	Domain

Pfam: PF03810, PF25795

UniProt features (8 total): modified residue 2, splice variant 2, sequence conflict 2, initiator methionine 1, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H2T7-F1	85.42	0.44

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 2, 569

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 108 (showing top): GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION_TO_ORGANELLE, GOMF_GTPASE_BINDING, GOBP_NUCLEAR_TRANSPORT, SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A4, GOBP_NUCLEOBASE_CONTAINING_COMPOUND_TRANSPORT, GOBP_PROTEIN_LOCALIZATION_TO_ORGANELLE, GOBP_NUCLEAR_EXPORT, GRYDER_PAX3FOXO1_ENHANCERS_IN_TADS, MODULE_207, GOBP_RNA_LOCALIZATION, GOBP_PROTEIN_LOCALIZATION_TO_NUCLEUS, GOCC_NUCLEAR_ENVELOPE, GOCC_NUCLEAR_PORE, GAZDA_DIAMOND_BLACKFAN_ANEMIA_ERYTHROID_DN

GO Biological Process (8): protein import into nucleus (GO:0006606), protein export from nucleus (GO:0006611), mRNA transport (GO:0051028), intracellular protein transport (GO:0006886), nucleocytoplasmic transport (GO:0006913), protein transport (GO:0015031), nuclear export (GO:0051168), nuclear transport (GO:0051169)

GO Molecular Function (3): nuclear export signal receptor activity (GO:0005049), GTP binding (GO:0005525), small GTPase binding (GO:0031267)

GO Cellular Component (3): nuclear pore (GO:0005643), cytoplasm (GO:0005737), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular protein transport	2
nuclear export	2
intracellular protein localization	2
intracellular transport	2
protein localization to nucleus	1
import into nucleus	1
establishment of protein localization to organelle	1
RNA transport	1
protein transport	1
nuclear transport	1
transport	1
establishment of protein localization	1
nucleocytoplasmic transport	1
intercellular transport	1
nucleocytoplasmic carrier activity	1
guanyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
GTPase binding	1
nuclear envelope	1
nuclear protein-containing complex	1
intracellular anatomical structure	1
cellular anatomical structure	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

706 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RANBP17	TLX3	O43711	797
RANBP17	TLX2	O43763	759
RANBP17	BCL11B	Q9C0K0	754
RANBP17	LYL1	P12980	648
RANBP17	XPO1	O14980	637
RANBP17	RANBP6	O60518	622
RANBP17	LMO1	P25800	615
RANBP17	TLX1	P31314	611
RANBP17	XPOT	O43592	578
RANBP17	CSE1L	P55060	550
RANBP17	TNPO2	O14787	545
RANBP17	IPO4	Q8TEX9	528
RANBP17	IPO5	O00410	506
RANBP17	TNPO1	Q92973	506
RANBP17	IPO11	Q9UI26	506

IntAct

7 interactions, top by confidence:

A	B	Type	Score
GYPB	TCAF2	psi-mi:“MI:0914”(association)	0.530
	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
RANBP17	TCERG1	psi-mi:“MI:0914”(association)	0.350
NPTN	RTL8C	psi-mi:“MI:0914”(association)	0.350
RANBP17	HMGA2	psi-mi:“MI:0914”(association)	0.350

BioGRID (22): RANBP17 (Affinity Capture-RNA), RANBP17 (Affinity Capture-RNA), RANBP17 (Affinity Capture-MS), RANBP17 (Affinity Capture-RNA), RANBP17 (Affinity Capture-MS), ACTA2 (Affinity Capture-MS), MUL1 (Affinity Capture-MS), EEF1A2 (Affinity Capture-MS), XPO7 (Affinity Capture-MS), CHRAC1 (Affinity Capture-MS), HMGA2 (Affinity Capture-MS), RANBP17 (Affinity Capture-MS), TCERG1 (Affinity Capture-MS), XPO7 (Affinity Capture-MS), XPO7 (Negative Genetic)

ESM2 similar proteins: A1CAU2, A1DEK2, A2QMS5, A5D785, A5WW24, A6RVT8, A7EPT5, B0Y4D6, B2AXG6, B8ARW2, B9FDR3, O13671, O13864, O14089, O18388, O43747, O59809, P14068, P30822, P33307, P55060, Q06142, Q0CIL3, Q1DY99, Q2H6R9, Q2U3V3, Q4WUV9, Q54EV7, Q569Z2, Q5R9G4, Q5R9J2, Q5ZLT0, Q6GMY9, Q704U0, Q7PC79, Q7RWV9, Q7SZC2, Q8AY73, Q8H0U4, Q8K2V6

Diamond homologs: Q54DN3, Q569Z2, Q5R9G4, Q5ZLT0, Q704U0, Q99NF8, Q9EPK7, Q9GQN0, Q9H2T7, Q9UIA9

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
RANBP17	up-regulates	TCF3	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

223 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	159
Likely benign	16
Benign	6

Top pathogenic / likely-pathogenic (0)

SpliceAI

6325 predictions. Top by Δscore:

Variant	Effect	Δscore
5:170862048:CCAG:C	donor_loss	1.0000
5:170862049:CAGGT:C	donor_loss	1.0000
5:170862050:AGGTC:A	donor_loss	1.0000
5:170862051:GGTC:G	donor_loss	1.0000
5:170862052:GTCA:G	donor_loss	1.0000
5:170878244:G:GG	donor_gain	1.0000
5:170881804:A:AG	acceptor_gain	1.0000
5:170881805:G:GG	acceptor_gain	1.0000
5:170881805:GAC:G	acceptor_gain	1.0000
5:170881894:TCA:T	donor_gain	1.0000
5:170881897:G:GG	donor_gain	1.0000
5:170892549:TCCAG:T	donor_loss	1.0000
5:170892550:CCAG:C	donor_loss	1.0000
5:170892551:CAGG:C	donor_loss	1.0000
5:170892552:AGG:A	donor_loss	1.0000
5:170892553:GG:G	donor_loss	1.0000
5:170892554:GTAA:G	donor_loss	1.0000
5:170892555:T:G	donor_loss	1.0000
5:170896141:GAGCC:G	donor_gain	1.0000
5:170896155:T:G	donor_gain	1.0000
5:170909656:TTTA:T	acceptor_loss	1.0000
5:170909659:A:AG	acceptor_gain	1.0000
5:170909659:AG:A	acceptor_gain	1.0000
5:170909659:AGGTT:A	acceptor_gain	1.0000
5:170909660:G:GG	acceptor_gain	1.0000
5:170909660:GG:G	acceptor_gain	1.0000
5:170909660:GGTT:G	acceptor_gain	1.0000
5:170909660:GGTTG:G	acceptor_gain	1.0000
5:170909762:AGAG:A	donor_gain	1.0000
5:170909762:AGAGG:A	donor_loss	1.0000

AlphaMissense

7165 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:170911125:T:A	W251R	1.000
5:170911125:T:C	W251R	1.000
5:170919486:T:A	W383R	1.000
5:170919486:T:C	W383R	1.000
5:171205557:G:A	G726R	1.000
5:171205557:G:C	G726R	1.000
5:170892485:T:A	W119R	0.999
5:170892485:T:C	W119R	0.999
5:170916499:G:C	R290T	0.999
5:170916499:G:T	R290I	0.999
5:170918746:T:C	C330R	0.999
5:170918747:G:A	C330Y	0.999
5:170918748:T:G	C330W	0.999
5:170918750:G:C	R331P	0.999
5:170918843:C:T	T362I	0.999
5:170918851:A:C	S365R	0.999
5:170918853:C:A	S365R	0.999
5:170918853:C:G	S365R	0.999
5:170918855:T:C	L366P	0.999
5:170919462:A:C	S375R	0.999
5:170919464:T:A	S375R	0.999
5:170919464:T:G	S375R	0.999
5:170919488:G:C	W383C	0.999
5:170919488:G:T	W383C	0.999
5:170953683:G:C	D519H	0.999
5:171205552:T:C	L724P	0.999
5:171205557:G:T	G726W	0.999
5:171205558:G:A	G726E	0.999
5:171221765:C:A	R783S	0.999
5:171296009:A:C	R1055S	0.999

dbSNP variants (sampled 300 via entrez): RS1000002188 (5:171020376 C>A), RS1000005393 (5:171236181 C>T), RS1000006793 (5:171160989 A>G), RS1000011330 (5:171292243 C>A), RS1000012964 (5:171111018 C>A,G,T), RS1000014554 (5:171053610 A>G), RS1000019760 (5:170942203 C>T), RS1000023412 (5:170983982 A>C,G), RS1000026440 (5:171290053 A>G), RS1000033879 (5:170909577 C>A,T), RS1000036215 (5:171282381 C>T), RS1000036698 (5:171236472 T>C), RS1000042025 (5:170942261 C>A), RS1000043972 (5:171022941 G>A), RS1000049534 (5:171030618 A>C,G)

Disease associations

OMIM: gene MIM:606141 | disease phenotypes: MIM:236600

GenCC curated gene-disease

Mondo (2): autism spectrum disorder (MONDO:0005258), congenital hydrocephalus (MONDO:0016349)

Orphanet (2): Congenital hydrocephalus (Orphanet:2185), NON RARE IN EUROPE: Autism (Orphanet:106)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST001525_3	Visceral fat	5.000000e-06
GCST005830_104	Hand grip strength	1.000000e-11
GCST006611_80	HDL cholesterol	2.000000e-14
GCST007327_4	Smoking status (ever vs never smokers)	3.000000e-10
GCST010242_214	HDL cholesterol levels	7.000000e-09
GCST010988_348	Adult body size	5.000000e-17
GCST011995_2	Restless legs syndrome	7.000000e-10
GCST012490_379	Femur bone mineral density x serum urate levels interaction	4.000000e-08
GCST90000047_113	Age at first sexual intercourse	2.000000e-09

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0006941	grip strength measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0004318	smoking behavior
EFO:0004531	urate measurement
EFO:0009749	age at first sexual intercourse measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

20 total (human), top 20 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression	3
Benzo(a)pyrene	affects methylation, increases methylation	2
aristolochic acid I	decreases expression	1
sodium arsenite	increases expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	decreases expression, affects cotreatment	1
jinfukang	affects cotreatment, decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Leflunomide	increases expression	1
Arsenic	increases expression	1
Cisplatin	affects cotreatment, decreases expression	1
Copper	affects cotreatment, decreases expression	1
Daunorubicin	affects response to substance	1
Methapyrilene	increases methylation	1
Testosterone	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Aflatoxin B1	increases methylation	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT01302964	PHASE3	COMPLETED	Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
NCT01706523	PHASE3	TERMINATED	Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
NCT01825798	PHASE3	COMPLETED	Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)
NCT01972074	PHASE3	COMPLETED	Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder
NCT02985749	PHASE3	COMPLETED	A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder
NCT03197922	PHASE3	COMPLETED	Treatment of Encopresis in Children With Autism Spectrum Disorders
NCT03504917	PHASE3	TERMINATED	A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
NCT03553875	PHASE3	TERMINATED	Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
NCT03640156	PHASE3	COMPLETED	Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin
NCT03715153	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
NCT03715166	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
NCT04233502	PHASE3	WITHDRAWN	Efficacy and Safety of Slenyto for Insomnia in Children With ASD
NCT04578756	PHASE3	COMPLETED	Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
NCT04623398	PHASE3	COMPLETED	Effect of Lithium in Patients With Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 Haploinsufficiency)
NCT04725383	PHASE3	TERMINATED	Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders
NCT05212493	PHASE3	COMPLETED	The Effects of Medical Cannabis in Children With Autistic Spectrum Disorder
NCT05361707	PHASE3	UNKNOWN	Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
NCT05439616	PHASE3	COMPLETED	Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD
NCT06229210	PHASE3	RECRUITING	Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder